Publication | Closed Access

Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec

Hematological MalignancyEarly Molecular ResponseOncologyMixed-phenotype Acute LeukemiaMalignant Blood DisorderHematologyPathologyComparative AnalysisAdult T-cell Leukemia-lymphomaMedicineCancer ResearchGeneric ImatinibMyeloid Neoplasia